Skip to content

Study · Not a test of the peptide alone · 2015

2 results

The glucose-lowering potential of exenatide delivered orally via goblet cell-targeting nanoparticles.

Li X, Wang C, Liang R, Sun F, Shi Y, Wang A, Liu W, Sun K, Li Y

Pharmaceutical research1 Oct 2014Cited by 32 (Europe PMC)

PMID25270570 (opens in a new tab)DOI10.1007/s11095-014-1513-1 (opens in a new tab)PepBankPUB-25270570
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 01AnimalNot a test of Exenatide (exendin-4) aloneOther designPharmacokinetics

    Modified exenatide nanoparticles had higher bioavailability than unmodified nanoparticles in an unspecified model.

    In plain wordsModified exenatide nanoparticles had higher bioavailability than unmodified nanoparticles in an unspecified model.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseBioavailability
    Study

    n: not reported in source

    Comparator
    unmodified nanoparticles
    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    bioavailability ratio
    1.7 fold
    modified versus unmodified nanoparticles

    Source sentences

    Summary
    The bioavailability of the modified nanoparticles was found to be 1.7-fold higher compared with the unmodified ones, and the hypoglycemic effect was also better.
    1 context sentence
    Summary · context
    The exenatide-loaded nanoparticles were prepared with modified chitosan which was conjugated with a goblet cell-target peptide, CSKSSDYQC (CSK) peptide.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 02AnimalNot a test of Exenatide (exendin-4) aloneOther designEfficacy outcome

    Modified exenatide nanoparticles had a better hypoglycemic effect than unmodified nanoparticles in an unspecified model.

    In plain wordsModified exenatide nanoparticles lowered glucose better than unmodified nanoparticles in an unspecified model.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseHypoglycemic effect
    Study

    n: not reported in source

    Comparator
    unmodified nanoparticles
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    The bioavailability of the modified nanoparticles was found to be 1.7-fold higher compared with the unmodified ones, and the hypoglycemic effect was also better.
    1 context sentence
    Summary · context
    The exenatide-loaded nanoparticles were prepared with modified chitosan which was conjugated with a goblet cell-target peptide, CSKSSDYQC (CSK) peptide.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.